Ultragenyx Pharmaceutical (RARE) Stock Price, Quote, News & History | Benzinga

SPY772.57+0.10%QQQ726.55−0.20%BTC/USD82,578.21+0.54%DIA521.44+0.05%GLD382.87+0.04%TLT79.77−0.25%

Ultragenyx Pharmaceutical Inc (RARE) Stock Price, Quote, News & History

RARENASDAQ

Trade with Public

Trade with Public

$15.17

0.271.81%

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

-

Close

$15.17

Volume / Avg.

- / 3.92M

Day Range

- - -

52 Wk Range

12.73 - 39.89

Market Cap

$1.47B

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

43

Short Interest

21.35%

Days to Cover

3.13

Recent Ultragenyx Pharmaceutical Inc. News

Ultragenyx Wins First Sanfilippo Approval As Analyst Keeps Ratings Modest

FDA approves Ultragenyx's Fayuvi for Sanfilippo syndrome Type A. Review commercial plans, $3.95 million pricing.

Vandana Singh

Ultragenyx Pharmaceutical (RARE) Stock Jumps After Hours: Here's Why It Is Trending

Ultragenyx shares rise after hours following FDA approval of FAYUVI, the first treatment approved for Sanfilippo syndrome Type A.

Mohd Haider

This Cal-Maine Foods Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday

Analysts downgraded UiPath, Cal-Maine with several price-target cuts.

Avi Kapoor

QUICK SPARK: Pharma Bro Martin Shkreli Says Ultragenyx Should Be M&A Target

Martin Shkreli calls Ultragenyx undervalued and a takeover target as the stock tanks after a trial failure.

Erica Kollmann

Gold Jumps 3%; ISM Services PMI Rises In August

U.S. stocks climbed, led by Dow’s 600-point gain; services PMI strengthened, Snowflake surged, while Ultragenyx plunged 44%.

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-485.00M

Investing Cash Flow (TTM)

40.00M

Financing Cash Flow (TTM)

397.00M

Free Cash Flow (TTM)

-494.00M

Capital Expenditure (TTM)

-9.00M

Net Change in Cash (TTM)

-

Analyst Trends and Forecast

1

Jul

10

Aug

13

6

Sep

1

Oct

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.7

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$852.58M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

2.13

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-38.41%

Earnings Yield % (FWD)

-4.68%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$2.95

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$125.00M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-